[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
This Week in JAMA
October 7, 2009

This Week in JAMA

JAMA. 2009;302(13):1395. doi:10.1001/jama.2009.1425

Lactoferrin—the major whey protein in mammalian milk—is involved in immune defense. In a placebo-controlled randomized trial, Manzoni and colleagues Article investigated whether oral administration of bovine lactoferrin, alone or in combination with the probiotic Lactobacillus rhamnosus GG, reduces the incidence of late-onset sepsis among very low-birth-weight neonates. The authors found that compared with infants who received placebo, the incidence of late-onset sepsis was significantly lower among infants who received bovine lactoferrin supplementation from birth until day 30 of life. In an editorial, Kaufman Article discusses the mechanisms of action of lactoferrin and prevention of nosocomial infections in preterm infants.